We focus on compelling targets for significant unmet medical needs where our deep expertise in assay development and enzymology gives us a competitive advantage and where there is a clear experimental path to a lead molecule.
Some of the key criteria for target selection include:
- Validated molecular target or pathway
- Opportunity for first-in-class
- Proprietary and/or enabling assay
- Good cellular and animal models
- Potential for companion diagnostic
- Low clinical barriers
TARGET |
INDICATIONS | STAGE |
---|---|---|
GEF-1 | Liver Fibrosis | Discovery |
GEF-2 | Age-related macular degeneration (AMD) | Discovery |
GEF-3 | Cancer (Multiple) | Discovery |
cGAS | Autoimmune -Systemic Lupus Erythematosus (SLE) -Aicardi-Goutieres Syndrome (AGS) |
Lead Identification |